AndhraNews.net
Home » Business News » 2011 » April » April 13, 2011

Karolinska Development invests in BioChromix


April 13, 2011 - Stockholm, Sweden

BioChromix AB, a Swedish in vitrodiagnostic companyfocusing on Alzheimer's disease, has received financing through a new shareissue directed to Karolinska Development. The new share issue will enableBioChromix to advance the development, validation and commercialization ofitsinnovative amyloid-beta (Aß) detection tools for the diagnosis andresearch ofneurodegenerative diseases, such as Alzheimer's disease. BioChromix iscurrentlyevaluating its technology in collaboration with a large pharmaceuticalcompany.

BioChromix is an innovative company that develops and commercializes uniqueproducts for early stage diagnostics of Alzheimer's disease. In parallel,thecompany is also developing a unique R&D assay with intended use for targetengagement during development of pharmaceuticals for Alzheimer's diseasethattarget Aß and to monitor the effectiveness of ongoing treatment.

Peter Åsberg, CEO, BioChromix:

"We have a clear goal - to bring our products for Alzheimer's disease tothemarket where urgent unmet diagnostic needs exist and where the company'suniqueLCP technology can have the greatest impact. The investment from KarolinskaDevelopment is a good measure of the progress BioChromix has made inadvancingits novel diagnostics platform. Being part of the Karolinska Developmentportfolio, will provide direct access to a broad network of keycompetencies andresources in the life-science industry which will be of great importanceforus."

Torbjørn Bjerke, CEO, Karolinska Development:

"BioChromix adds to an already strong portfolio of innovative CNS projectsinKarolinska Development's portfolio. In addition, this investmentstrengthens ourengagement in fighting Alzheimer's disease - a progressive severe form ofsenileDementia that is growing in prevalence along with an ageing population."

After the new share issue, Karolinska Development holds an eight percentownership in BioChromix. The investment also increases KarolinskaDevelopment'sindirect ownership in BioChromix Pharma, a pharmaceutical company owned byBioChromix and Karolinska Development. BioChromix Pharma is active inresearchand development of novel treatments for neurodegenerative disorders basedon aproprietary technology for therapeutics.


TO THE EDITORS

About BioChromix

BioChromix is an innovative company active on the life science arena thatdevelops and commercializes unique products for early stage diagnostics ofAlzheimer's disease (AD). In parallel, the Company also develops a uniqueR&Dassay with intended use for target engagement during development ofpharmaceuticals for AD that target amyloid-beta and to monitor theeffectivenessof ongoing treatment. The Company's methods are based on our novel andpatentedLuminescent Conjugated Polymer (LCP) molecules. The Company is fastadvancingthe in vitro pipeline in order to bring our lead product candidates forAlzheimer's disease to the market. www.biochromix.com

About Karolinska Development

Karolinska Development aims to create value for investors, patients, andresearchers by developing innovations from world class research intoproductsthat can be sold or out-licensed with high returns. The business model isto:SELECT the most commercially attractive medical innovations; DEVELOP thesetothe stage where the greatest return on investment can be achieved; andCOMMERCIALIZE the innovations through the sale of companies or outlicensing ofproducts. This will result in upfront payments, milestone payments androyalties.

An exclusive deal flow agreement with Karolinska Institutet Innovations AB,along with other cooperation agreements with leading Nordic universities,delivers a continuous flow of innovations.

Karolinska Development's flexible exit strategy enables projects to beexited atwhichever stage of development offers the greatest return on investment,usuallyafter Phase II clinical trials have indicated the desired pharmaceuticaleffecton patients - this being an important value enhancing step.

Today, the portfolio consists of over 40 projects at various stages, fromconcept development to Phase II clinical trials, twelve projects are inclinicaltrials with six in Phase II. The portfolio is particularly strong in theareasof cancer, dermatology, inflammation, cardiovascular disease, women'shealth anddiseases that affect the central nervous system.www.karolinskadevelopment.com


Read press release as PDF:http://hugin.info/143071/R/1505754/440621.pdf


This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Karolinska Development AB (publ) via Thomson Reuters ONE

[HUG#1505754]

For further information, please contact:
Peter Asberg
CEO
BioChromix AB
Phone: +46 70 949 17 21
e-mail: Email Contact

Torbjorn Bjerke
CEO
Karolinska Development AB
Phone: +46 72 744 41 23
e-mail: Email Contact

MarketWire

Comment on this story

Share